PSOGI World News — January 2026: What Patients and Caregivers Should Know

A quarterly newsletter with the latest news, views and announcements from Peritoneal Surface Oncology Group International (PSOGI)

Led by pioneering surgical oncologist Dr. Paul Sugarbaker, PSOGI is a collaboration of experts from around the world on the treatment of peritoneal cancer and is dedicated to improving treatment and survival of patients with peritoneal metastases.

We are proud to share their quarterly newsletter.

---

The latest issue of PSOGI World News, the quarterly newsletter from the Peritoneal Surface Oncology Group International (PSOGI), offers updates from experts around the world who are working to improve care for patients with peritoneal surface malignancies — cancers that spread to the lining of the abdomen. PSOGI brings together leading surgical oncologists and researchers to share scientific progress, clinical insights, and global collaboration on these rare and complex diseases.

While the full January 2026 newsletter is intended largely for medical professionals, it reinforces the importance of evidence-based approaches — including standardized methods for cytoreductive surgery and related care — that are relevant to peritoneal cancer treatment planning and patient discussions.

Key Highlights from the Winter 2026 Edition

The latest issue of PSOGI World News shares emerging global perspectives on treating gastric cancer with peritoneal metastases, with a strong focus on evolving intraperitoneal treatment strategies. Experts highlight how care is increasingly moving toward multimodal, personalized approaches that combine systemic chemotherapy, surgery, and regional therapies such as HIPEC, NIPS, and PIPAC to improve outcomes for carefully selected patients.

A major theme throughout this issue is determining which patients benefit most from aggressive regional therapies and how treatment sequencing can safely improve survival while maintaining quality of life. Ongoing research continues to refine patient selection, treatment timing, and drug delivery approaches within specialized centers.

Key Clinical Questions Discussed

1. Does HIPEC following gastrectomy and peritonectomy remain an option for patients with peritoneal metastases and PCI ≤6? Yes — current practice continues to consider cytoreductive surgery (including gastrectomy and peritonectomy) followed by HIPEC a potential treatment option for highly selected patients with limited peritoneal disease burden (low PCI) treated in experienced centers. Evidence suggests survival benefit may be achievable without significantly increasing postoperative complications when appropriate patient selection is used.

2. Is NIPS (normothermic intraperitoneal and systemic chemotherapy) with repeated IV and intraperitoneal paclitaxel a leading option for efficacy and safety? NIPS is increasingly viewed as a promising neoadjuvant strategy, combining systemic chemotherapy with repeated intraperitoneal delivery through a port. Studies show it can reduce tumor burden, control ascites, and improve the likelihood of later surgical treatment while maintaining acceptable safety profiles.

3. Is conversion surgery after NIPS a major treatment goal? Yes. A central objective of NIPS therapy is achieving sufficient disease response to allow conversion surgery—meaning patients initially considered unresectable may become candidates for cytoreductive surgery after treatment response. This approach reflects a growing shift toward attempting curative-intent treatment in selected patients with peritoneal metastases.

4. Is PIPAC a treatment option, and which drugs are used? PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) is recognized as a treatment option, particularly for patients who are not candidates for immediate cytoreductive surgery. It is most often used for disease control or palliation and may be alternated with systemic chemotherapy. Common intraperitoneal agents include cisplatin and doxorubicin, or oxaliplatin-based regimens, depending on treatment protocols and tumor type.

Upcoming Education and Events: PSOGI continues to promote educational opportunities, workshops, and global meetings where clinicians can learn about the latest surgical techniques, research findings, and treatment strategies. These events help ensure physicians stay current with evolving approaches in peritoneal oncology.

Why This Matters for Patients

These discussions reflect an important reality: treatment for peritoneal metastases from gastric cancer is rapidly evolving. Increasingly, patients may benefit from specialized evaluation at experienced peritoneal surface malignancy centers, where advanced regional therapies and clinical trials are available.

The PSOGI World News reflects a shared commitment among global experts to broaden understanding, support clinical research, and improve the journey for patients facing peritoneal surface malignancies.

Read the full January 2026 issue of PSOGI World News here:

Read more